Therapeutic targeting of altered airway microbiota to prevent lung damage and pneumonia in mice with cystic fibrosis-like lung disease (B08*)

以改变气道微生物群为治疗目标，预防囊性纤维化样肺病小鼠的肺损伤和肺炎 (B08*)

• 批准号: 405350508
• 金额: --
• 依托单位: Klinik für Pädiatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin (CVK)
• 依托单位国家: 德国
• 项目类别: CRC/Transregios
• 财政年份: 2018
• 资助国家: 德国
• 起止时间: 2017-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/405350508?language=en
• 关键词: Therapeutic; targeting; altered; airway; microbiota

Alterations in airway microbiota are associated with severity of lung disease in patients with cystic fibrosis (CF). However, the role of disordered microbiota in the in vivo pathogenesis and as therapeutic target in CF lung disease remains unknown. In this project, we will therefore use a unique mouse model of CF lung disease and state-of-the-art next generation sequencing i) to determine the role of altered airway microbiota in CF-like airway inflammation and structural lung damage; ii) to test if therapeutic targeting of abnormal microbiota can reduce these abnormalities; and iii) to test if such a therapeutic approach can reduce susceptibility to Pseudomonas aeruginosa infection characteristic of CF lung disease in vivo.

囊性纤维化（CF）患者气道微生物群的改变与肺部疾病的严重程度相关。然而，紊乱的微生物群在体内发病机制中的作用以及作为CF肺部疾病的治疗靶点仍然未知。因此，在这个项目中，我们将使用一种独特的CF肺病小鼠模型和最先进的下一代测序来确定气道微生物群改变在CF样气道炎症和结构性肺损伤中的作用；Ii)测试针对异常微生物群的治疗是否可以减少这些异常；iii)测试这种治疗方法是否可以降低体内对CF肺病特有的铜绿假单胞菌感染的易感性。